China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
PHOENIX, Nov. 18, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Piper Jaffray 28th Annual Healthcare Conference as follows:
| Date: | Wednesday, November 30, 2016 | |
| Time: | 9:30 a.m. Eastern Standard Time | |
| Location: | Lotte New York Palace, New York |
The presentations will be webcast live at the aforementioned times as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROSTM (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROSTM are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: [email protected]
